Market Overview

UPDATE: Jefferies Upgrades Sequenom to Buy on Reimbursement Coverage Outlook

Share:
Related SQNM
Benzinga's M&A Chatter for Wednesday July 27, 2016
Mid-Afternoon Market Update: Crude Oil Down 2.5%; Sequenom Shares Spike Higher

Jefferies raised its rating on Sequenom (NASDAQ: SQNM) from Hold to Buy with a reiterated $7 price target.

Jefferies said, "We are upgrading shares of SQNM to Buy (from Hold) based on results from a proprietary survey we conducted of US commercial payors representing some 44 million lives, which indicated SQNM is experiencing meaningful traction obtaining reimbursement coverage for its T21 LDT test at average rates that we find more than acceptable. Our $7 price target (>90% upside) is unchanged."

Sequenom closed at $3.60 on Friday.

Latest Ratings for SQNM

DateFirmActionFromTo
Mar 2016Ladenburg ThalmannUpgradesSellNeutral
Sep 2015JefferiesDowngradesBuyHold
Sep 2015William BlairDowngradesMarket Perform

View More Analyst Ratings for SQNM
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (SQNM)

View Comments and Join the Discussion!